Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Receives Average Recommendation of "Moderate Buy" from Brokerages

Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the six research firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $27.50.

Several analysts have recently commented on KMTS shares. Stifel Nicolaus initiated coverage on Kestra Medical Technologies in a research report on Monday, March 31st. They issued a "buy" rating and a $28.00 target price for the company. Piper Sandler started coverage on Kestra Medical Technologies in a research report on Monday, March 31st. They set an "overweight" rating and a $27.00 price objective for the company. Wells Fargo & Company started coverage on Kestra Medical Technologies in a report on Monday, March 31st. They issued an "overweight" rating and a $28.00 target price on the stock. The Goldman Sachs Group reduced their price target on shares of Kestra Medical Technologies from $24.00 to $23.00 and set a "neutral" rating for the company in a research report on Wednesday, April 16th. Finally, Bank of America began coverage on shares of Kestra Medical Technologies in a research report on Monday, March 31st. They set a "buy" rating and a $30.00 price objective on the stock.

Kestra Medical Technologies Stock Performance

NASDAQ KMTS opened at $24.24 on Tuesday. Kestra Medical Technologies has a 12 month low of $20.00 and a 12 month high of $26.15. The stock has a 50 day simple moving average of $23.68.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last released its earnings results on Monday, April 14th. The company reported ($1.25) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.61). During the same period last year, the firm earned ($1.18) EPS.

Institutional Investors Weigh In On Kestra Medical Technologies

A number of large investors have recently bought and sold shares of KMTS. Yu Fan bought a new position in Kestra Medical Technologies during the first quarter valued at about $56,880,000. T. Rowe Price Investment Management Inc. bought a new stake in Kestra Medical Technologies during the first quarter worth approximately $56,613,000. Omega Fund Management LLC acquired a new position in Kestra Medical Technologies during the first quarter valued at approximately $44,754,000. Alliancebernstein L.P. bought a new position in shares of Kestra Medical Technologies in the first quarter valued at approximately $29,500,000. Finally, Brown Advisory Inc. acquired a new stake in shares of Kestra Medical Technologies in the first quarter worth $13,716,000.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.